**This week in therapeutics**

<table>
<thead>
<tr>
<th>Indication</th>
<th>Target/marker/pathway</th>
<th>Summary</th>
<th>Licensing status</th>
<th>Publication and contact information</th>
</tr>
</thead>
</table>
Contact: Eric B. Haura, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Fla.  
e-mail: eric.haura@moffitt.org |
| Lung cancer | AXL receptor tyrosine kinase (AXL; UFO); discoidin domain receptor tyrosine kinase 2 (DDR2); c-Met proto-oncogene (MET; HGFR); insulin-like growth factor-1 receptor (IGF1R; CD221) | Mouse studies suggest inhibitors of IGF1R, MET and AXL could synergize with Sprycel dasatinib to help treat lung squamous cell cancers (SCCs) with activating DDR2 mutations. In DDR2-mutant human lung SCC cell lines, dasatinib decreased viability but increased activation of IGF1R, AXL, MET and other cancer-associated kinases compared with vehicle. In the DDR2-mutant SCC cells, dasatinib plus small molecule inhibitors of IGF1R or AXL and MET synergistically decreased viability compared with any agent alone. Next steps could include testing combinations of dasatinib and IGF1R or AXL and MET inhibitors in animal models of SCC. | }}

Bristol-Myers Squibb Co. and Otsuka Pharmaceutical Co. Ltd. market the BCR-ABL tyrosine kinase inhibitor Sprycel to treat chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL).

*SciBX* 7(47); doi:10.1038/scibx.2014.1372  
Published online Dec. 11, 2014